Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRα-positive, platinum-resistant ovarian cancer. - Konecny, Gottfried; Moore, Kathleen; Lebreton, Coriolan; Weroha, Saravut; Marin, Margarita Romeo; McAvan, Lucy; Colombo, Nicoletta; O'Malley, David; Coffman, Lan; Roszak, Andrzej; Shapira-Frommer, Ronnie; Lalisang, Roy; et al. (Gynecologic Oncology, 2024)